Literature DB >> 19289119

Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro.

Mie Hirohata1, Kenjiro Ono, Akiyoshi Morinaga, Tokuhei Ikeda, Masahito Yamada.   

Abstract

The alpha-synuclein aggregation in the brain is the hallmark of Lewy body diseases, including Parkinson's disease and dementia with Lewy bodies, and multiple system atrophy. Some epidemiological studies have revealed that estrogen therapy reduces the risk of Parkinson's disease in females. We examined the effects of estriol, estradiol, estrone, androstenedione, and testosterone on the formation and destabilization of alpha-synuclein fibrils at pH 7.5 and 37 degrees C in vitro, using fluorescence spectroscopy with thioflavin S and electron microscopy. These sex hormones, especially estriol, significantly exert anti-aggregation and fibril-destabilizing effects; and hence, could be valuable preventive and therapeutic agents for alpha-synucleinopathies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19289119     DOI: 10.1016/j.expneurol.2009.03.003

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  13 in total

1.  Formulations of hormone therapy and risk of Parkinson's disease.

Authors:  Jessica I Lundin; Thanh G N Ton; Andrea Z LaCroix; W T Longstreth; Gary M Franklin; Phillip D Swanson; Terri Smith-Weller; Brad A Racette; Harvey Checkoway
Journal:  Mov Disord       Date:  2014-09-25       Impact factor: 10.338

Review 2.  Sex Differences in Dopaminergic Vulnerability to Environmental Toxicants - Implications for Parkinson's Disease.

Authors:  Ashley Adamson; Silas A Buck; Zachary Freyberg; Briana R De Miranda
Journal:  Curr Environ Health Rep       Date:  2022-10-06

Review 3.  Gender differences in Parkinson's disease: focus on plasma α-synuclein.

Authors:  Giovanni Caranci; Paola Piscopo; Roberto Rivabene; Anna Traficante; Barbara Riozzi; Anna Elisa Castellano; Stefano Ruggieri; Nicola Vanacore; Annamaria Confaloni
Journal:  J Neural Transm (Vienna)       Date:  2013-01-18       Impact factor: 3.575

4.  Exploring the Transition of Human α-Synuclein from Native to the Fibrillar State: Insights into the Pathogenesis of Parkinson's Disease.

Authors:  Naveed Ahmad Fazili; Aabgeena Naeem
Journal:  J Fluoresc       Date:  2016-06-30       Impact factor: 2.217

5.  Hormone replacement therapy and risk for neurodegenerative diseases.

Authors:  Richelin V Dye; Karen J Miller; Elyse J Singer; Andrew J Levine
Journal:  Int J Alzheimers Dis       Date:  2012-04-04

6.  Estrogen receptor activation contributes to RNF146 expression and neuroprotection in Parkinson's disease models.

Authors:  Hyojung Kim; Sangwoo Ham; Joon Yeop Lee; Areum Jo; Gum Hwa Lee; Yun-Song Lee; MyoungLae Cho; Heung-Mook Shin; Donghoon Kim; Olga Pletnikova; Juan C Troncoso; Joo-Ho Shin; Yun-Il Lee; Yunjong Lee
Journal:  Oncotarget       Date:  2017-10-11

7.  Effects of Pinealectomy and Gonadectomy on Olfactory Bulb Dopaminergic Neurons in Rats.

Authors:  Yan Li; Jian Zhu; Ying Wang; Lei Guo; Lei Li; Dong Wang
Journal:  Chin Med J (Engl)       Date:  2017-10-05       Impact factor: 2.628

8.  In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson's disease.

Authors:  Takeshi Uenaka; Wataru Satake; Pei-Chieng Cha; Hideki Hayakawa; Kousuke Baba; Shiying Jiang; Kazuhiro Kobayashi; Motoi Kanagawa; Yukinori Okada; Hideki Mochizuki; Tatsushi Toda
Journal:  Hum Mol Genet       Date:  2018-11-15       Impact factor: 6.150

9.  Gender Differences in Age-Related Striatal Dopamine Depletion in Parkinson's Disease.

Authors:  Jae Jung Lee; Jee Hyun Ham; Phil Hyu Lee; Young H Sohn
Journal:  J Mov Disord       Date:  2015-09-10

10.  Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies.

Authors:  M van de Beek; R Babapour Mofrad; I van Steenoven; H Vanderstichele; P Scheltens; C E Teunissen; A W Lemstra; W M van der Flier
Journal:  Alzheimers Res Ther       Date:  2020-04-17       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.